Li and colleagues tested BETi action on MYC activity and found that in both MYC/BCL2 DHL and MYC/BCL2/BCL6, triple-hit lymphoma cells were responsive to BETi (JQ1, I-BET, OTX) treatment [86]. Here, BCL2 is linked to lymphoma.